Download PDF
Aktuelle Neurologie 2010; 37(9): 438-446
DOI: 10.1055/s-0030-1248565
Neues in der Neurologie

© Georg Thieme Verlag KG Stuttgart · New York

Neues zu Kopfschmerzen 2010

What's New in Headache 2010?H.-C.  Diener1 , C.  Gaul1 , D.  Holle1 , C.  Sommer2
  • 1Universitätsklinik für Neurologie und Westdeutsches Kopfschmerz-Zentrum, Essen
  • 2Neurologische Klinik, Universitätsklinikum Würzburg
Further Information

Publication History

Publication Date:
19 October 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

In den letzten Monaten wurden verschiedene innovative Studien veröffentlicht, die maßgeblich zum Verständnis von Kopf- und Gesichtsschmerzen sowie neuropathischen Schmerzen beigetragen haben. Dieser Artikel berichtet über wichtige Forschungsergebnisse, die sich mit verschiedenen epidemiologischen, pathophysiologischen, genetischen sowie therapeutischen Fragestellungen auseinandergesetzt haben. Themenschwerpunkte liegen u. a. auf Triggerfaktoren der Migräne, Therapie und Epidemiologie der chronischen Migräne, Risikofaktoren für vaskuläre Ereignisse bei Migränepatienten, malignes Hirnödem bei Subtypen der Migräne, neue Behandlungsmöglichkeiten in der Akuttherapie (5-HT1F-Agonisten, CGRP-Antagonisten), innovative Applikationsformen für Sumatriptan. Außerdem wird über neue Behandlungsoptionen für trigemino-autonome Kopfschmerzen berichtet. Eine weitere interessante zerebrale Bildgebungsstudie bei posttraumatischen Kopfschmerzen wird vorgestellt, die zeigt, dass schmerzassoziierte Veränderungen der grauen Substanz vermutlich reversibel sind. Die klinische Relevanz der berichteten Studienergebnisse wird beleuchtet.

Abstract

During the last months several innovative studies that contribute to the understanding of headache as well as facial and neuropathic pain have been published. This review highlights important research topics in this field including epidemiology, pathophysiology, genetics and treatment options. Here we summarise, amongst other topics, work on trigger factors in migraine, treatment and epidemiology of chronic migraine, risk of vascular events in migrane patients, malignant brain oedema in subtypes of migraine, new acute treatment options (5-HT1F agonists, CGRP antagonists), and innovative administration forms for sumatriptan. Additionally, the newest insights in the therapy of trigemino autonomic cephalgias are discussed. Interesting neuroimaging data on post-traumatic headache that suggest a reversibility of pain-associated gray matter changes are presented. The clinical relevance of the reported study results is evaluated.

Schlüsselwörter

Kopfschmerzen - chronische Migräne - Pathophysiologie - Therapie

Keywords

headache - chronic migraine - pathophysiology - treatment

Literatur

  • 1 Hauge A, Kirchmann M, Olesen J. Trigger factors in migraine with aura.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 2 Natoli J, Manack A, Dean B. et al . Global prevalence of chronic migraine: a systematic review.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 3 Silberstein S D, Lipton R B, Solomon S. et al . Classification of daily or near-daily headaches: proposed revisions to the IHS criteria.  Headache. 1994;  34 1-7
    PubMedGoogle Scholar
  • 4 Kurth T, Slomke M A, Kase C S. et al . Migraine, headache, and the risk of stroke in women: a prospective study.  Neurology. 2005;  64 1020-1026
    CrossrefPubMedGoogle Scholar
  • 5 Schurks M, Rist P M, Bigal M E. et al . Migraine and cardiovascular disease: systematic review and meta-analysis.  BMJ. 2009;  339 b3914
    CrossrefPubMedGoogle Scholar
  • 6 Bigal M E, Kurth T, Santanello N. et al . Migraine and cardiovascular disease: a population-based study.  Neurology. 2010;  74 628-635
    CrossrefPubMedGoogle Scholar
  • 7 Kurth T, Ridker P M, Buring J E. Migraine and biomarkers of cardiovascular disease in women.  Cephalalgia. 2008;  28 49-56
    CrossrefPubMedGoogle Scholar
  • 8 Tietjen G E, Brandes J L, Peterlin B L. et al . Childhood maltreatment and migraine (part III). Association with comorbid pain conditions.  Headache. 2009 [epub ahead of print]; 
    Google Scholar
  • 9 Tietjen G E, Brandes J L, Peterlin B L. et al . Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification.  Headache. 2010;  50 32-41
    CrossrefPubMedGoogle Scholar
  • 10 Tietjen G E, Brandes J L, Peterlin B L. et al . Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: a multicenter headache clinic survey.  Headache. 2010;  50 20-31
    CrossrefPubMedGoogle Scholar
  • 11 Peterlin B L, Rosso A L, Rapoport A M. et al . Obesity and migraine: The effect of age, gender and adipose tissue distribution.  Headache. 2010;  50 52-62
    CrossrefPubMedGoogle Scholar
  • 12 Bigal M E, Liberman J N, Lipton R B. Obesity and migraine: a population study.  Neurology. 2006;  66 545-550
    CrossrefPubMedGoogle Scholar
  • 13 Bigal M E, Lipton R B. Obesity is a risk factor for transformed migraine but not chronic tension-type headache.  Neurology. 2006;  67 252-257
    CrossrefPubMedGoogle Scholar
  • 14 Mattsson P. Migraine headache and obesity in women aged 40–74 years: a population-based study.  Cephalalgia. 2007;  27 877-880
    CrossrefPubMedGoogle Scholar
  • 15 Bigal M E, Gironda M, Tepper S J. et al . Headache prevention outcome and body mass index.  Cephalalgia. 2006;  26 445-450
    CrossrefPubMedGoogle Scholar
  • 16 Kors E E, Terwindt G M, Vermeulen F LMG. et al . Delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine.  Ann Neurol. 2001;  49 753-760
    CrossrefPubMedGoogle Scholar
  • 17 Stam A H, Luijckx G J, Poll-The B T. et al . Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation.  J Neurol Neurosurg Psychiatry. 2009;  80 1125-1129
    CrossrefPubMedGoogle Scholar
  • 18 Stewart W F, Wood G C, Manack A. et al . Employment and work impact of chronic migraine and episodic migraine.  J Occup Environ Med. 2010;  52 8-14
    PubMedGoogle Scholar
  • 19 Suthisisang C C, Poolsup N, Suksomboon N. et al . Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine.  Headache. 2010;  50 808-818
    CrossrefPubMedGoogle Scholar
  • 20 Prior M J, Codispoti J R, Fu M. A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache.  Headache. 2010;  50 819-833
    CrossrefPubMedGoogle Scholar
  • 21 Anneken K, Evers S, Husstedt I W. Efficacy of fixed combinations of acetylsalicyclic acid, acetaminophen and caffeine in the treatment of idiopathic headache: a review.  Eur J Neurol. 2010;  17 534-540
    CrossrefPubMedGoogle Scholar
  • 22 Ferrari M, Färkkilä M, Reuter U. et al . Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomized proof-of-concept study.  Cephalalgia. , doi DOI: 10.1177/0333102410375512
    PubMedGoogle Scholar
  • 23 Goadsby P J, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine.  Cephalalgia. 1991;  11 (Suppl. 11) 3-4
    PubMedGoogle Scholar
  • 24 Goadsby P J. Evidence of the involvement of CGRP in migraine and cluster headache: a physiological perspective. In: Poyner D, Marshall I, Brain S, eds The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Georgetown, Texas; Landes Bioscience 2000: 159-165
    Google Scholar
  • 25 Olesen J, Diener H, Husstedt I W. et al . Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks.  N Engl J Med. 2004;  350 1104-1110
    CrossrefPubMedGoogle Scholar
  • 26 Ho T W, Mannix L K, Fan X. et al . Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.  Neurology. 2008;  70 1304-1312
    CrossrefPubMedGoogle Scholar
  • 27 Connor K M, Shapiro R E, Diener H C. et al . Randomized, controlled trial of telcagepant for the acute treatment of migraine.  Neurology. 2009;  73 970-977
    CrossrefPubMedGoogle Scholar
  • 28 Brandes J L, Cady R K, Freitag F G. et al . Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use.  Headache. 2009;  49 1435-1444
    CrossrefPubMedGoogle Scholar
  • 29 Gillmann P K. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review.  Headache. 2010;  50 264-272
    CrossrefPubMedGoogle Scholar
  • 30 Cunnington M, Ephross S, Churchill P. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?.  Headache. 2009;  49 1414-1422
    CrossrefPubMedGoogle Scholar
  • 31 Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.  Headache. 2010;  50 563-575
    CrossrefPubMedGoogle Scholar
  • 32 Olesen C, Steffensen F H, Sorensen H T. et al . Pregnancy outcome following prescription for sumatriptan.  Headache. 2000;  40 20-24
    CrossrefPubMedGoogle Scholar
  • 33 O'Quinn S, Ephross S A, Williams V. et al . Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study.  Arch Gynecol Obstet. 1999;  263 7-12
    CrossrefPubMedGoogle Scholar
  • 34 Fox A W, Chambers C D, Anderson P O. et al . Evidence-based assessment of pregnancy outcome after sumatriptan exposure.  Headache. 2002;  42 8-15
    CrossrefPubMedGoogle Scholar
  • 35 Fiore M, Shields K E, Santanello N. et al . Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004.  Cephalalgia. 2005;  25 685-688
    CrossrefPubMedGoogle Scholar
  • 36 Chen H M, Chen S F, Chen Y H. et al . Increased risk of adverse pregnancy outcomes for women with migraines: a nationwide population-based study.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 37 Lipton R B, Dodick D W, Silberstein S D. et al . Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.  Lancet Neurol. 2010;  9 373-380
    CrossrefPubMedGoogle Scholar
  • 38 Dodick D W, Freitag F, Banks J. et al . Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.  Clin Ther. 2009;  31 542-559
    CrossrefPubMedGoogle Scholar
  • 39 Lampl C, Huber G, Adl J. et al . Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors.  Eur J Neurol. 2009;  16 943-948
    CrossrefPubMedGoogle Scholar
  • 40 Diener H C, Bussone G, Van Oene J. et al . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.  Cephalalgia. 2007;  27 814-823
    CrossrefPubMedGoogle Scholar
  • 41 Diener H C, Dodick D W, Goadsby P J. et al . Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse.  Cephalalgia. 2009;  29 1021-1027
    CrossrefPubMedGoogle Scholar
  • 42 Silberstein S D, Lipton R B, Dodick D W. et al . Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.  Headache. 2007;  47 170-180
    CrossrefPubMedGoogle Scholar
  • 43 Reuter U, Del Rio M S, Diener H C. et al . Migraines with and without aura and their response to preventive therapy with topiramate.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 44 Aurora S, Dodick D, Turkel C. et al . OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.  Cephalalgia. 2010;  , first published on March 17, 2010 as doi: DOI: 10.1177/0333102410364676
    Google Scholar
  • 45 Diener H, Dodick D, Aurora S. et al . OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.  Cephalalgia. 2010;  , first published on March 17, 2010 as doi: DOI: 10.1177/0333102410364677
    Google Scholar
  • 46 Dodick D, Turkel C, DrGryse R. et al . OnabotulinumA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programme.  Headache. 2010; in press; 
    Google Scholar
  • 47 Petri S, Tolle T, Straube A. et al . Botulinum toxin as preventive treatment for migraine: a randomized double-blind study.  Eur Neurol. 2009;  62 204-211
    CrossrefPubMedGoogle Scholar
  • 48 Teepker M, Hotzel J, Timmesfeld N. et al . Low-frequency rTMS of the vertex in the prophylactic treatment of migraine.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 49 Schwedt T J, Dodick D W, Hentz J. et al . Occipital nerve stimulation for chronic headache – long-term safety and efficacy.  Cephalalgia. 2007;  27 153-157
    CrossrefPubMedGoogle Scholar
  • 50 Paemeleire K, Van Buyten J P, Van Buynder M. et al . Phenotype of patients responsive to occipital nerve stimulation for refractory head pain.  Cephalalgia. 2010;  30 662-673
    PubMedGoogle Scholar
  • 51 Guyuron B, Reed D, Kriegler J S. et al . A placebo-controlled surgical trial of the treatment of migraine headaches.  Plast Reconstr Surg. 2009;  124 461-468
    CrossrefPubMedGoogle Scholar
  • 52 Gaul C, Holle D, Sandor P. et al . The value of „migraine surgery”: overview of the pathophysiological concept and current evidence.  Nervenarzt. 2010 Feb 26. [Epub ahead of print] German;  , PubMed PMID 20182856
    Google Scholar
  • 53 Newman L, Mannix L K, Landy S. et al . Naratriptan as short-term prophylaxis in menstrually associated migraine: a randomised, double-blind, placebo-controlled study.  Headache. 2001;  41 248-256
    CrossrefPubMedGoogle Scholar
  • 54 Mannix L K, Savani N, Landy S. et al . Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.  Headache. 2007;  47 1037-1049
    CrossrefPubMedGoogle Scholar
  • 55 Silberstein S D, Berner T, Tobin J. et al . Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation.  Headache. 2009;  49 1283-1297
    CrossrefPubMedGoogle Scholar
  • 56 Brandes J L, Poole A, Kallela M. et al . Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.  Cephalalgia. 2009;  29 1133-1148
    CrossrefPubMedGoogle Scholar
  • 57 MacGregor E A, Brandes J L, Silberstein S. et al . Safety and tolerability of short-term preventive frovatriptan: a combined analysis.  Headache. 2009;  49 1298-1314
    CrossrefPubMedGoogle Scholar
  • 58 Straube A, Pfaffenrath V, Ladwig K H. et al . Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 59 Scher A I, Lipton R B, Stewart W F. et al . Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 60 Fontanillas N, Colas R, Munoz P. et al . Long-term evolution of chronic daily headache with medication overuse in the general population.  Headache. 2010;  50 981-988
    CrossrefPubMedGoogle Scholar
  • 61 Sances G, Ghiotto N, Galli F. et al . Risk factors in medication-overuse headache: a 1-year follow-up study (care II protocol).  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 62 Cittadini E, May A, Straube A. et al . Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study.  Arch Neurol. 2006;  63 1537-1542
    CrossrefPubMedGoogle Scholar
  • 63 Rapoport A M, Mathew N T, Silberstein S D. et al . Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study.  Neurology. 2007;  69 821-826
    CrossrefPubMedGoogle Scholar
  • 64 Hedlund C, Rapoport A M, Dodick D W. et al . Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies.  Headache. 2009;  49 1315-1323
    CrossrefPubMedGoogle Scholar
  • 65 Cohen A S, Burns B, Goadsby P J. High-flow oxygen for treatment of cluster headache: a randomized trial.  JAMA. 2009;  302 2451-2457
    CrossrefPubMedGoogle Scholar
  • 66 Anthony M. Arrest of attacks of cluster headache by local steroid injection of the occipital nerve. In: Rose FC, ed Migraine: Clinical and Research Advances. London; Karger 1985: 169-173
    Google Scholar
  • 67 Burns B, Watkins L, Goadsby P J. Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study.  Lancet Neurol. 2008;  7 1001-1012
    CrossrefPubMedGoogle Scholar
  • 68 Magis D, Allena M, Bolla M. et al . Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study.  Lancet Neurol. 2007;  6 314-321
    CrossrefPubMedGoogle Scholar
  • 69 Leone M, Proietti C A, Franzini A. et al . Lessons from 8 years' experience of hypothalamic stimulation in cluster headache.  Cephalalgia. 2008;  28 787-797
    CrossrefPubMedGoogle Scholar
  • 70 Leone M, Franzini A, Broggi G. et al . Hypothalamic stimulation for intractable cluster headache: long-term experience.  Neurology. 2006;  67 150-152
    CrossrefPubMedGoogle Scholar
  • 71 Leone M, Franzini A, Broggi G. et al . Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow up.  J Neurol Sci. 2003;  24 (Suppl. 2) 143-145
    PubMedGoogle Scholar
  • 72 Bartsch T, Pinsker M O, Rasche D. et al . Hypothalamic deep brain stimulation for cluster headache: experience from a new multicase series.  Cephalalgia. 2008;  28 285-295
    CrossrefPubMedGoogle Scholar
  • 73 Fontaine D, Lazorthes Y, Mertens P. et al . Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension.  J Headache Pain. 2010;  11 23-31
    CrossrefPubMedGoogle Scholar
  • 74 Obermann M, Nebel K, Riegel A. et al . Incidence and predictors of chronic headache attributed to whiplash injury.  Cephalalgia. 2009 [epub ahead of print]; 
    Google Scholar
  • 75 Obermann M, Nebel K, Schumann C. et al . Gray matter changes related to chronic posttraumatic headache.  Neurology. 2009;  73 978-983
    CrossrefPubMedGoogle Scholar
  • 76 Cittadini E, Goadsby P J. Hemicrania continua: a clinical study of 39 patients with diagnostic implications.  Brain. 2010;  133 1973-1986
    CrossrefPubMedGoogle Scholar
  • 77 Lanteri-Minet M, Donnet A. Hypnic headache.  Curr Pain Headache Rep. 2010;  14 309-315
    CrossrefPubMedGoogle Scholar

Prof. Dr. Hans-Christoph Diener

Neurologischen Klinik und Poliklinik
Universität Duisburg-Essen

Hufelandstr. 55

45147 Essen

Email: hans.diener@uni-due.de